drugset / Trial / NCT04489446

Sildenafil in COVID-19

NCT04489446 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This randomised trial aims to assess the role of sildenafil in improving oxygenation amongst hospitalised patients with COVID19.

Timeline

Start
2020-08-19
Primary completion
2021-04-30
Completion
2021-06-30

Outcome

Missed primary endpoint

paper No significant differences in mean PaO2/FiO2 ratios and A-a gradients were found between groups (repeated-measures ANOVA p = 0.67 and p = 0.69). PMID 34980198 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 25 mg Oral

Indications